Physician profile
Errin Manney
NPI 1912386236
$4,380.84
in general payments reported to CMS, 2019-2025
38 companies · $1,139 in 2025
The $1,139 reported for 2025 was more than what 88% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $106 · 2020: $55.35 · 2021: $17.84 · 2022: $628 · 2023: $1,381 · 2024: $1,053 · 2025: $1,139.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,574.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,573.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $695.76 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Abbvie INC. | $627.91 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $444.11 | 2022-2025 | Jardiance, Spiriva Respimat |
| Lilly USA, LLC | $422.31 | 2022-2025 | Mounjaro, Jardiance, Zepbound |
| Pfizer INC. | $274.74 | 2024-2025 | |
| Amgen INC. | $189.36 | 2022-2025 | Evenity, Prolia, Prolia |
| Exact Sciences Corporation | $167.46 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Glaxosmithkline, LLC. | $143.66 | 2022-2025 | Shingrix, Arexvy, Bexsero |
| Astrazeneca Pharmaceuticals LP | $139.25 | 2022-2025 | Farxiga, Airsupra |
| Abbott Laboratories | $125.35 | 2023 | Freestyle Libre 3 |
| Janssen Pharmaceuticals, INC | $118.07 | 2022-2024 | Spravato, Xarelto |
| Bayer Healthcare Pharmaceuticals INC. | $101.71 | 2022-2023 | |
| Organon LLC | $83.87 | 2022-2025 | Nexplanon |
| Dexcom, INC. | $75.11 | 2025 | Dexcom G6 Transmitter |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $69.81 | 2022-2025 | Xifaxan |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $60.00 | 2019-2024 | Capvaxive, Gardasil, Gardasil 9 |
| Ardelyx, INC. | $59.94 | 2025 | Ibsrela |
| Phathom Pharmaceuticals, INC. | $57.97 | 2023-2024 | Voquezna |
| Idorsia Pharmaceuticals US INC | $57.96 | 2023-2024 | Quviviq |
| Corcept Therapeutics | $48.33 | 2025 | Korlym |
| Novartis Pharmaceuticals Corporation | $47.46 | 2021-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $45.16 | 2022 | |
| Philips North America LLC | $39.05 | 2023 | |
| Otsuka America Pharmaceutical, INC. | $38.16 | 2025 | Rexulti |
| Astellas Pharma US INC | $35.66 | 2025 | Veozah |
| Kowa Pharmaceuticals America, INC. | $30.38 | 2025 | Zoryve |
| Takeda Pharmaceuticals U.S.A., INC. | $28.18 | 2023 | Vpriv |
| Esperion Therapeutics, INC. | $27.93 | 2024 | Nexletol |
| Inspire Medical Systems, INC. | $26.13 | 2024 | Inspire |
| Sanofi Pasteur INC. | $20.42 | 2019 | |
| Mylan Specialty L.P. | $19.52 | 2022 | |
| Currax Pharmaceuticals LLC | $17.02 | 2023 | Contrave |
| Exeltis, USA INC. | $15.01 | 2025 | Slynd |
| Scynexis, INC. | $14.18 | 2022 | |
| Lundbeck LLC | $13.90 | 2023 | Rexulti |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Errin Manney listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.